Abstract: The present invention relates to a set-up and a method for measuring color of a turbid liquid giving a result matching a visual observation.

Abstract: The disclosure is related to an apparatus and method for charged hadron therapy verification. The apparatus comprises a collimator comprising a plurality of collimator slabs of a given thickness, spaced apart so as to form an array of mutually slit-shaped openings, configured to be placed at a right angle to the beam line, so as to allow the passage of prompt gammas from the target, the collimator being defined at least by three geometrical parameters being the width and depth of the slit-shaped openings and a fill factor. The disclosure is also related to a method for charged hadron therapy verification with a multi-slit camera.

Abstract: The present invention relates to electronic power converter suitable, in a first mode, for receiving electrical voltage and/or current magnitudes from a first device as input, for processing them using processing means capable of measuring said electrical magnitudes and servocontrolling said electrical magnitudes based on said measurements and constraints specific to a second device, and for providing the adapted voltage and/or current magnitudes to said second device.

Abstract: The present invention concerns a microfluidic device (1) for performing physical, chemical or biological treatment to at least one packet without contamination.

Abstract: The present invention relates, inter alia, to recombinant Gram-positive Clostridia host cells for producing solvents, fuels and/or chemical intermediates, and preferably ethanol, from plant cell walls comprising: (a) at least one nucleic acid encoding a plant cell wall degrading enzyme, wherein the host cells produce and secrete the plant cell wall degrading enzyme, (b) at least one nucleic acid encoding an enzyme that converts pyruvate to acetaldehyde and at least one nucleic acid encoding an enzyme that converts acetaldehyde to ethanol wherein the host cell is capable of expressing said nucleic acid, and, (c) a mutation in at least one nucleic acid encoding for an enzyme in a metabolic pathway which produces a metabolite other than acetaldehyde from pyruvate or ethanol from acetaldehyde, such that the mutation results in a reduced production of the metabolite.

Abstract: Described herein are molecules, constructs and methods for the production and secretion of polypeptides of interest by host cells, preferably bacterial host cells, and more particularly gram positive bacteria. In particular, the present invention is related to a polynucleic acid encoding a fusion protein and to uses thereof for the secretion of heterologous or homologous polypeptides of interest by a bacterial host cell, preferably Clostridium bacteria. The present invention further relates to methods and constructs for the production and secretion of heterologous or homologous polypeptides of interest proteins by host cells using such polynucleic acids and fusion proteins.

Abstract: The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal 1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.

Abstract: The invention provides methods of treating diseases, disorsers or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a Sema6A polypeptide.

Abstract: The invention relates to a rear casing for a turbine engine comprising a primary body generating a primary flow (10) to be ejected through a primary nozzle (6), said rear casing (7) being shaped so as to be positioned downstream from the primary body and to define, on the inside of the turbine engine, the path followed by the primary flow downstream from the primary nozzle (6). The tail cone is characterised in that it comprises a connection to a system for supplying a pressurised gas and at least one perforation (8) for injecting the pressurised gas through the perforation and into the primary flow. The casing preferably comprises at least one means for rotating same about the axis of rotation of the mobile elements of the primary body.

Abstract: A phantom for medical imaging instrumentation, the phantom including a first hydrogel matrix, said matrix containing additives for simulating the optical and acoustic properties of a living organ or tissue. In the phantom, the additives include Indian ink or haemoglobin, silica powder and titanium dioxide powder. The phantom may contain a tumor simulator in solid or liquid form. It may also comprise several hydrogel matrices, each matrix including additives in different concentrations depending on the organ or tissue simulated. A method of producing the phantom includes one or more freeze-thaw cycles for optimizing the characteristics of the phantom.

Abstract: The invention relates to applications of the cellulase Cel5H of Saccharophagus degradans and its homologues, functional fragments and/or variants and engineered forms thereof, in the context of recombinant, more particularly solventogenic microorganisms, more particularly C. acetobutylicum. The invention also characterizes a novel domain of the Cel5H cellulase with a putative cellulose-binding module function, and its uses in chimeric proteins for depolymerization of cellulose containing substrates.

Abstract: A method for grafting a porous element for leucodepletion by adsorption and/or filtration of a biological fluid, such as blood or a blood component, which method comprises the steps of impregnating the porous element with a solution containing a poly(ethylene oxide) having identical or different functional end groups; and applying an ionizing treatment to the impregnated porous element so as to ensure covalent cross-linking between the poly(ethylene oxide) and the porous element.

Abstract: According to the invention, the intermediate sheath (13) is formed by assembling longitudinal elements (13A) and includes: a first optical material, the refractive index of which differs from the refractive index of the monomode core by at most 10?3; and a second optical material, the refractive index of which is lower than the refractive index of said monomode core and differs therefrom by at least 10?3.

Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

Abstract: A memory cell is provided with a transistor which includes source and drain electrodes formed in a semiconductor film by respectively N-doped and P-doped areas. The transistor includes first and second devices for generating a potential barrier in the semiconductor film. The two potential barriers are shifted laterally and are opposed to the passage of the charge carriers emitted by the nearest source/drain electrode. One of the devices for generating the potential barrier is electrically connected to the gate. The other of the devices for generating the potential barrier is electrically connected to the counter-electrode. The writing of a high state is carried out by imposing on the P-doped electrode a potential higher than that of the N-doped electrode and charging the capacitor formed between the gate and the semiconductor film. The resetting of the memory cell is obtained by discharging the capacitor.

Abstract: The invention relates to the use of cyclovinyl phosphine compounds in the form of complexes with copper, as catalysts for reactions leading to the formation of carbon-carbon and carbon-heteroatom bonds. The invention also relates to complexes of copper with at least one cyclovinyl phosphine, as well as to the method for creating a carbon-carbon or a carbon-heteroatom bond catalysed by a cyclovinyl phosphine/copper complex.

Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

Abstract: An emulsifying composition, characterised in that it contains by weight, excluding impurities, (i) 1 to 98% by weight of a mixture of alkyl glycosides R1O(G1)g1(G2)g2(G3)g3(G4)g4(G5)g5, (ii) 1 to 90% by weight of a mixture of alcohol esters R2OZ, (iii) 1 to 90% of an alcohol R3OH, and (iv) 4 to 90% of a mixture of alkyl glycoside esters R4O(X1)x1(Z)z1(X2)x2(Z)z2(X3)x3(Z)z3(X4)x4(Z)z4(X5)x5(Z)z5, is disclosed In accordance with the composition, R1 is a hydrocarbon radical, linear or branched, saturated or unsaturated, having 10 to 22 carbon atoms. G1, G2, G3, G4, G5 are identical or different residues of -oses selected from glucose, galactose, mannose, fructose, ribose, xylose and arabinose, g1, g2, g3, g4 and g5 being equal to 0 or 1, the sum of g1, g2, g3, g4 and g5 being at least equal to 1. The composition has emulsifying capacity in the presence of electrolytes or in the case of paraffin-based emulsions.

Abstract: Continuous time analogue/digital converter, comprising a sigma delta modulator (MSD1) configured to receive an analogue input signal (x(t)) and comprising high-pass filtering means (MF) the chopping frequency of which is equal to half of the sampling frequency (Fs) of the quantization means (QTZ) of the modulator (MSD1).

Abstract: The present invention relates, inter alia, to recombinant Gram-positive Clostridia host cells for producing solvents, fuels and/or chemical intermediates, and preferably ethanol, from plant cell walls comprising: (a) at least one nucleic acid encoding a plant cell wall degrading enzyme, wherein the host cells produce and secrete the plant cell wall degrading enzyme, (b) at least one nucleic acid encoding an enzyme that converts pyruvate to acetaldehyde and at least one nucleic acid encoding an enzyme that converts acetaldehyde to ethanol wherein the host cell is capable of expressing said nucleic acid, and, (c) a mutation in at least one nucleic acid encoding for an enzyme in a metabolic pathway which produces a metabolite other than acetaldehyde from pyruvate or ethanol from acetaldehyde, such that the mutation results in a reduced production of the metabolite.